Brean Murray Carret & Co. Maintains a 'Buy' Pharmasset (VRUS); Abbott (ABT) Hep C Pipeline Not More Risky Than Any Other Four Drug Combo

Brean Murray Carret & Co. maintains a 'Buy' Pharmasset (NASDAQ: VRUS) price target of $105.00.

Brean analyst said, "We believe the market sharply overreacted to data from Abbott (NYSE: ABT)(Hold) last week indicating that a four drug combination is capable of achieving high SVR rates in genotype 1 patients. We believe that there are a multitude of four drug combinations that can achieve this hurdle and do not believe Abbott is positioned with a regimen that is competitive with a PSI-7977 based combination."

For more ratings news on Pharmasset click here and for the rating history of Pharmasset click here.

Shares of Pharmasset closed at $72.54 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
• Unicycive Therapeutics (UNCY) PT Raised to $15 at Benchmark Following Q2 Results
• Jefferies Downgrades Sunway Healthcare Holdings (SUNMED:MK) to Hold